Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vend...
May 06 2016 - 12:46PM
Business Wire
Research and Markets has announced the addition of the
"Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1,
2016" clinical trials to their offering.
The clinical trial report, Tachycardia (Tachyarrhythmias) Global
Clinical Trials Review, H1, 2016" provides an overview of
Tachycardia (Tachyarrhythmias) clinical trials scenario. This
report provides top line data relating to the clinical trials on
Tachycardia (Tachyarrhythmias). Report includes an overview of
trial numbers and their average enrollment in top countries
conducted across the globe. The report offers coverage of disease
clinical trials by region, country (G7 & E7), phase, trial
status, end points status and sponsor type.
The report enhances the decision making capabilities and helps
to create an effective counter strategies to gain competitive
advantage.
Key Topics Covered:
- The report provides a snapshot of the global clinical trials
landscape
- The report provides top level data related to the clinical
trials by Region, Country (G7 & E7), Trial Status, Trial Phase,
Sponsor Type and End point status
- The report reviews top companies involved and enlists all
trials (Trial title, Phase, and Status) pertaining to the
company
- The report provides all the unaccomplished trials (Terminated,
Suspended and Withdrawn) with reason for unaccomplishment
- The report provides enrollment trends for the past five
years
- The report provides latest news for the past three months
Reasons to Buy:
- Assists in formulating key business strategies with regards to
investment
- Helps in identifying prominent locations for conducting
clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market
which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by
country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by
providing a comparative scenario of completed and uncompleted
(terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a
global, regional and country level
Companies Mentioned:
- Johnson & Johnson
- St. Jude Medical, Inc.
- Ono Pharmaceutical Co., Ltd.
- Gilead Sciences, Inc.
- Chemo Espana, S.A.
- Medtronic plc
- Aop Orphan Pharmaceuticals AG
- Allergan Plc
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Armgo Pharma, Inc.
For more information visit
http://www.researchandmarkets.com/research/tkn7ss/tachycardia
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160506005635/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716